Developer docs
API playgroundTry for free, no card

Search company profiles

Avadel Pharmaceuticals

Full company profile

uuid0000wvn

Namestring
Avadel Pharmaceuticals
Legal namestring
Avadel Pharmaceuticals plc
Websiteurl
avadel.com
Company typeenum
Public
Founded yearint
1990
Descriptiontext

Avadel Pharmaceuticals was a commercial-stage biopharmaceutical company incorporated in Ireland (Dublin headquarters) with U.S. operations based in Chesterbrook, Pennsylvania, focused on developing and commercializing treatments for sleep disorders and central nervous system conditions. Its core asset was LUMRYZ (sodium oxybate), an FDA-approved extended-release oral suspension and the first and only once-at-bedtime oxybate therapy indicated for cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy, with adult approval in May 2023 and pediatric expansion in October 2024. The underlying technology is a proprietary extended-release sodium oxybate formulation that replaces the twice-nightly dosing of legacy oxybate products (Jazz's Xyrem and Xywav) with a single bedtime dose, an attribute that drove 48% year-over-year patient growth and 55% year-over-year revenue growth to $77.5 million in Q3 2025.

The pipeline was anchored by valiloxybate, an in-licensed salt-free, sweetener-free once-at-bedtime oxybate candidate in Phase 1 development acquired from XWPharma in September 2025 for $20 million upfront plus up to $185 million in milestones. Avadel generated revenue almost entirely from LUMRYZ product sales distributed exclusively through the certified LUMRYZ REMS specialty pharmacy network, targeting sleep specialists and neurologists across a U.S. addressable population of more than 50,000 oxybate-eligible narcolepsy patients; pricing was not publicly disclosed. After a competitive bidding process triggered by Lundbeck's November 2025 unsolicited offer, Avadel was acquired by Alkermes plc for up to $2.37 billion (including contingent value rights tied to FDA milestones) through an Irish High Court-sanctioned scheme of arrangement that closed on February 12, 2026, financed with $775 million of cash and $1.525 billion in term loans due 2031. Post-acquisition, Avadel operates as a wholly-owned subsidiary of Alkermes and is no longer a standalone reporting entity.

Short descriptiontext

Avadel Pharmaceuticals was a commercial-stage biopharmaceutical company that developed and marketed LUMRYZ, an FDA-approved once-at-bedtime extended-release sodium oxybate for narcolepsy patients aged 7 and older. Acquired by Alkermes plc in February 2026 for up to $2.37 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
narcolepsy treatment, sleep medicine pharmaceuticals, extended-release oxybate, CNS therapeutics, specialty biopharmaceuticals
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Narcolepsy Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1LUMRYZ Product Sales
TypeOne Time License
Description

Revenue from sales of FDA-approved LUMRYZ (sodium oxybate) for narcolepsy. Net product revenue of $77.5 million in Q3 2025, representing 55% year-over-year growth. Approximately 3,400-3,600 patients on therapy.

biospace.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Operations, Marketing or Sales, Technology or R&D, Personnel
Pricing details1 tier
1LUMRYZ (sodium oxybate) for extended-release oral suspension - pricing not publicly disclosed
ModelOtherBilling cadenceMonthly
Notes

Product available through restricted LUMRYZ REMS program. Specific pricing not disclosed in available sources.

investor.alkermes.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LUMRYZ
Description

FDA-approved extended-release sodium oxybate medication for cataplexy or excessive daytime sleepiness in narcolepsy patients (adults and pediatric 7+ years). First and only once-at-bedtime oxybate treatment.

biospace.com
Core offering1 text field

Avadel Pharmaceuticals develops and commercializes LUMRYZ (sodium oxybate), an FDA-approved extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. LUMRYZ is the first and only once-at-bedtime sodium oxybate therapy, distributed through a restricted REMS program. The pipeline includes valiloxybate, an in-licensed once-at-bedtime, salt-free oxybate candidate for narcolepsy and idiopathic hypersomnia.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Avadel Pharmaceuticals was a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for sleep disorders and central nervous system conditions. The company's commercial portfolio centered on LUMRYZ (sodium oxybate), an FDA-approved extended-release oxybate therapy for narcolepsy. The pipeline included valiloxybate, an in-licensed Phase 1 oxybate candidate. Avadel was acquired by Alkermes plc in February 2026 for approximately $2.1 billion, adding LUMRYZ and Avadel's commercial infrastructure to Alkermes' portfolio.

Product and service2 records
1LUMRYZ (sodium oxybate) for extended-release oral suspension
CategoryNarcolepsy Therapeutics
Description

LUMRYZ is an extended-release oral suspension formulation of sodium oxybate, FDA-approved as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. It is being evaluated for idiopathic hypersomnia indication through the Phase 3 REVITALYZ trial. Distributed only through the restricted LUMRYZ REMS program via certified specialty pharmacies to enrolled prescribers.

2Valiloxybate (XNW01)
CategoryPipeline Candidate
Description

Valiloxybate is a once-at-bedtime, salt-free and artificial sweetener-free oxybate therapy candidate in Phase 1 clinical development for the treatment of narcolepsy and idiopathic hypersomnia. In-licensed from XWPharma under an exclusive global license agreement.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-22
Description

Global settlement resolving all litigation related to oxybate products. Jazz paid $90 million to Avadel and the companies entered mutual licensing agreements concerning patents and future product sales. This agreement provided Avadel with IP clarity and strategic certainty for the LUMRYZ product.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Exclusive global license agreement to develop and commercialize valiloxybate (XNW01), a once-at-bedtime, salt-free and artificial sweetener-free oxybate therapy for narcolepsy and idiopathic hypersomnia. XWPharma received $20 million upfront with potential development milestones up to $30 million, performance-based sales milestones up to $155 million for net sales up to $750 million, and tiered royalties.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Jazz Pharmaceuticals markets Xyrem and Xywav, the established twice-nightly oxybate therapies for narcolepsy, and was Avadel's principal competitor and litigation counterparty. Jazz's franchise occupies the same oxybate mechanism, prescriber base (sleep specialists/neurologists), and patient pool that LUMRYZ targets, making it the most directly comparable peer.

TypeDirect peer
Description

Harmony Biosciences commercializes Wakix (pitolisant), a non-oxybate treatment for excessive daytime sleepiness in narcolepsy, competing for the same specialist prescriber audience and patient population. Its focused CNS/sleep commercial organization and single-product narcolepsy franchise make it a closely analogous specialty biopharma peer.

TypeBroad incumbent
Description

Takeda markets oveporexton (TAK-861), an orexin receptor agonist in late-stage development for narcolepsy, and has a broader CNS/neuroscience portfolio. It represents a large incumbent with emerging competitive overlap in narcolepsy, though its franchise extends well beyond sleep disorders.

TypeBroad incumbent
Description

Alkermes acquired Avadel in February 2026 and is advancing alixorexton, an orexin receptor agonist in Phase 3 for narcolepsy. As the new parent and a CNS-focused biopharma with overlapping sleep medicine ambitions, Alkermes is both the strategic acquirer and a future in-house competitor/partner in the narcolepsy space.

TypeEmerging player
Description

Axsome Therapeutics is a CNS-focused biopharma developing therapies for narcolepsy and other neurological conditions, with a specialty commercial model targeting the same sleep specialist prescriber base. Its emerging narcolepsy pipeline and focused neuroscience commercial strategy make it a relevant emerging peer.

TypeEmerging player
Description

NLS Pharmaceuticals is developing Quilience (mazindol ER), a treatment for narcolepsy, with a focused small-team approach targeting the same sleep medicine specialist channel. As an emerging specialty narcolepsy-focused player, it is comparable to Avadel's pre-launch commercial-stage model.

TypeBroad incumbent
Description

Sumitomo Pharma (formerly Sunovion/Sumitomo Dainippon) developed pitolisant-related sleep assets and maintains a broader CNS portfolio. It overlaps with Avadel in narcolepsy and adjacent sleep disorder therapeutics, though its franchise spans multiple therapeutic areas.

8Eisai Co.
TypeBroad incumbent
Description

Eisai is a major CNS biopharma with sleep-disorder and neurology franchises, including orexin pathway interest and historical narcolepsy/insomnia products. As a large incumbent with strategic overlap in sleep medicine, it provides a relevant adjacent comparable for category dynamics.

TypeBroad incumbent
Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avadel Pharmaceuticals

Narcolepsy Therapeuticsavadel.com

Avadel Pharmaceuticals was a commercial-stage biopharmaceutical company that developed and marketed LUMRYZ, an FDA-approved once-at-bedtime extended-release sodium oxybate for narcolepsy patients aged 7 and older. Acquired by Alkermes plc in February 2026 for up to $2.37 billion.

What Avadel Pharmaceuticals does

Avadel Pharmaceuticals was a commercial-stage biopharmaceutical company incorporated in Ireland (Dublin headquarters) with U.S. operations based in Chesterbrook, Pennsylvania, focused on developing and commercializing treatments for sleep disorders and central nervous system conditions. Its core asset was LUMRYZ (sodium oxybate), an FDA-approved extended-release oral suspension and the first and only once-at-bedtime oxybate therapy indicated for cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy, with adult approval in May 2023 and pediatric expansion in October 2024. The underlying technology is a proprietary extended-release sodium oxybate formulation that replaces the twice-nightly dosing of legacy oxybate products (Jazz's Xyrem and Xywav) with a single bedtime dose, an attribute that drove 48% year-over-year patient growth and 55% year-over-year revenue growth to $77.5 million in Q3 2025.

The pipeline was anchored by valiloxybate, an in-licensed salt-free, sweetener-free once-at-bedtime oxybate candidate in Phase 1 development acquired from XWPharma in September 2025 for $20 million upfront plus up to $185 million in milestones. Avadel generated revenue almost entirely from LUMRYZ product sales distributed exclusively through the certified LUMRYZ REMS specialty pharmacy network, targeting sleep specialists and neurologists across a U.S. addressable population of more than 50,000 oxybate-eligible narcolepsy patients; pricing was not publicly disclosed. After a competitive bidding process triggered by Lundbeck's November 2025 unsolicited offer, Avadel was acquired by Alkermes plc for up to $2.37 billion (including contingent value rights tied to FDA milestones) through an Irish High Court-sanctioned scheme of arrangement that closed on February 12, 2026, financed with $775 million of cash and $1.525 billion in term loans due 2031. Post-acquisition, Avadel operates as a wholly-owned subsidiary of Alkermes and is no longer a standalone reporting entity.

Avadel Pharmaceuticals firmographics

Firmographics
Name
Avadel Pharmaceuticals
Legal name
Avadel Pharmaceuticals plc
Website
https://avadel.com
Company type
Public
Founded year
1990
Operating status
Acquired
Headcount range
101–250 employees
Short description
Avadel Pharmaceuticals was a commercial-stage biopharmaceutical company that developed and marketed LUMRYZ, an FDA-approved once-at-bedtime extended-release sodium oxybate for narcolepsy patients aged 7 and older. Acquired by Alkermes plc in February 2026 for up to $2.37 billion.
Ownership category
akta.pro rank

Where Avadel Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices2 records

Markets served

Avadel Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Marketing or Sales, Technology or R&D, Personnel

Revenue model

  1. LUMRYZ Product Sales: Revenue from sales of FDA-approved LUMRYZ (sodium oxybate) for narcolepsy. Net product revenue of $77.5 million in Q3 2025, representing 55% year-over-year growth. Approximately 3,400-3,600 patients on therapy.

Pricing tiers

ModelBillingPrice
OtherMonthlyLUMRYZ (sodium oxybate) for extended-release oral suspension - pricing not publicly disclosed

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Avadel Pharmaceuticals product offering

Product offering

Core offering

Avadel Pharmaceuticals develops and commercializes LUMRYZ (sodium oxybate), an FDA-approved extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. LUMRYZ is the first and only once-at-bedtime sodium oxybate therapy, distributed through a restricted REMS program. The pipeline includes valiloxybate, an in-licensed once-at-bedtime, salt-free oxybate candidate for narcolepsy and idiopathic hypersomnia.

Product overview

Avadel Pharmaceuticals was a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for sleep disorders and central nervous system conditions. The company's commercial portfolio centered on LUMRYZ (sodium oxybate), an FDA-approved extended-release oxybate therapy for narcolepsy. The pipeline included valiloxybate, an in-licensed Phase 1 oxybate candidate. Avadel was acquired by Alkermes plc in February 2026 for approximately $2.1 billion, adding LUMRYZ and Avadel's commercial infrastructure to Alkermes' portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • LUMRYZ: FDA-approved extended-release sodium oxybate medication for cataplexy or excessive daytime sleepiness in narcolepsy patients (adults and pediatric 7+ years). First and only once-at-bedtime oxybate treatment.

Products and services

  • LUMRYZ (sodium oxybate) for extended-release oral suspension LUMRYZ is an extended-release oral suspension formulation of sodium oxybate, FDA-approved as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. It is being evaluated for idiopathic hypersomnia indication through the Phase 3 REVITALYZ trial. Distributed only through the restricted LUMRYZ REMS program via certified specialty pharmacies to enrolled prescribers.
  • Valiloxybate (XNW01) Valiloxybate is a once-at-bedtime, salt-free and artificial sweetener-free oxybate therapy candidate in Phase 1 clinical development for the treatment of narcolepsy and idiopathic hypersomnia. In-licensed from XWPharma under an exclusive global license agreement.

Companies that use Avadel Pharmaceuticals

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Avadel Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Avadel Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Jazz PharmaceuticalscoreStrategic or Co-development Partner · 22 October 2025Global settlement resolving all litigation related to oxybate products. Jazz paid $90 million to Avadel and the companies entered mutual licensing agreements concerning patents and future product sales. This agreement provided Avadel with IP clarity and strategic certainty for the LUMRYZ product.
  • XWPharmacoreStrategic or Co-development Partner · 3 September 2025Exclusive global license agreement to develop and commercialize valiloxybate (XNW01), a once-at-bedtime, salt-free and artificial sweetener-free oxybate therapy for narcolepsy and idiopathic hypersomnia. XWPharma received $20 million upfront with potential development milestones up to $30 million, performance-based sales milestones up to $155 million for net sales up to $750 million, and tiered royalties.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Avadel Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals: Jazz Pharmaceuticals markets Xyrem and Xywav, the established twice-nightly oxybate therapies for narcolepsy, and was Avadel's principal competitor and litigation counterparty. Jazz's franchise occupies the same oxybate mechanism, prescriber base (sleep specialists/neurologists), and patient pool that LUMRYZ targets, making it the most directly comparable peer.
  • Harmony Biosciences: Harmony Biosciences commercializes Wakix (pitolisant), a non-oxybate treatment for excessive daytime sleepiness in narcolepsy, competing for the same specialist prescriber audience and patient population. Its focused CNS/sleep commercial organization and single-product narcolepsy franchise make it a closely analogous specialty biopharma peer.

Broad incumbents

  • Takeda Pharmaceutical: Takeda markets oveporexton (TAK-861), an orexin receptor agonist in late-stage development for narcolepsy, and has a broader CNS/neuroscience portfolio. It represents a large incumbent with emerging competitive overlap in narcolepsy, though its franchise extends well beyond sleep disorders.
  • Alkermes plc: Alkermes acquired Avadel in February 2026 and is advancing alixorexton, an orexin receptor agonist in Phase 3 for narcolepsy. As the new parent and a CNS-focused biopharma with overlapping sleep medicine ambitions, Alkermes is both the strategic acquirer and a future in-house competitor/partner in the narcolepsy space.
  • Sumitomo Pharma America: Sumitomo Pharma (formerly Sunovion/Sumitomo Dainippon) developed pitolisant-related sleep assets and maintains a broader CNS portfolio. It overlaps with Avadel in narcolepsy and adjacent sleep disorder therapeutics, though its franchise spans multiple therapeutic areas.
  • Eisai Co. Eisai is a major CNS biopharma with sleep-disorder and neurology franchises, including orexin pathway interest and historical narcolepsy/insomnia products. As a large incumbent with strategic overlap in sleep medicine, it provides a relevant adjacent comparable for category dynamics.
  • Lundbeck:

Emerging players

  • Axsome Therapeutics: Axsome Therapeutics is a CNS-focused biopharma developing therapies for narcolepsy and other neurological conditions, with a specialty commercial model targeting the same sleep specialist prescriber base. Its emerging narcolepsy pipeline and focused neuroscience commercial strategy make it a relevant emerging peer.
  • NLS Pharmaceuticals: NLS Pharmaceuticals is developing Quilience (mazindol ER), a treatment for narcolepsy, with a focused small-team approach targeting the same sleep medicine specialist channel. As an emerging specialty narcolepsy-focused player, it is comparable to Avadel's pre-launch commercial-stage model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Avadel Pharmaceuticals social profiles

Digital presence

Avadel Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avadel Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Avadel Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Avadel Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avadel Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avadel Pharmaceuticals

What does Avadel Pharmaceuticals do?

Avadel Pharmaceuticals develops and commercializes LUMRYZ (sodium oxybate), an FDA-approved extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. LUMRYZ is the first and only once-at-bedtime sodium oxybate therapy, distributed through a restricted REMS program. The pipeline includes valiloxybate, an in-licensed once-at-bedtime, salt-free oxybate candidate for narcolepsy and idiopathic hypersomnia.

Is Avadel Pharmaceuticals a public or private company?

Avadel Pharmaceuticals is a public company. It is classified as public and is currently acquired.

When was Avadel Pharmaceuticals founded?

Avadel Pharmaceuticals was founded in 1990. It employs 101 to 250 people.

Where is Avadel Pharmaceuticals based?

Avadel Pharmaceuticals is headquartered in Dublin, Ireland, in the Europe region.

How does Avadel Pharmaceuticals make money?

One revenue line is on record: LUMRYZ Product Sales.

Who are Avadel Pharmaceuticals's main competitors?

Direct peers on record are Jazz Pharmaceuticals and Harmony Biosciences. Broad incumbents are Takeda Pharmaceutical, Alkermes plc, Sumitomo Pharma America, Eisai Co. and Lundbeck. Emerging players are Axsome Therapeutics and NLS Pharmaceuticals.

Does Avadel Pharmaceuticals have an API?

No public API is recorded for Avadel Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialNarcolepsy Pipeline Outlook 2026: Oral, Injectable, And Novel Delivery Candidates Advancing Through Clinical Trials Novartis, Shionogi Inc., Takeda, Avadel Pharma, Harmony Biosciences, Jazz PharmaTakeda's Phase III trials of oveporexton met primary endpoints in September 2026, showing significant improvements in wakefulness and cataplexy. Axsome Therapeutics received FDA approval for its NDA for AXS-12 (reboxetine) for cataplexy, with a PDUFA date of May 1, 2027. Harmony Biosciences reported favorable Phase I results for BP-205, with Phase II trials expected in mid-2027.The Pharma LetterMentari names former Avadel chief Greg Divis as CEOMentari Therapeutics, a privately-held Waltham, Massachusetts-based biotech company, has appointed Greg Divis as its new chief executive officer and member of its board. Divis previously served as CEO of Avadel Pharmaceuticals, where he led the development, US approval and commercial launch of the narcolepsy treatment Lumryz (sodium oxybate). Avadel was acquired by Alkermes earlier this year in a deal valued at up to $2.4 billion.AInvestGranules: first-to-file ANDA status for Lumryz genericThe FDA has not yet approved a generic version of Lumryz (sodium oxybate) as of July 2026, with no first-to-file ANDA approved for this extended-release narcolepsy treatment. Lumryz, developed by Avadel Pharmaceuticals, received its first approval on May 1, 2023, and remains under market exclusivity with no generic competition on the horizon. The absence of a first generic approval indicates the drug continues to be distributed exclusively through Avadel under a restricted REMS program as a Schedule III controlled substance.DrugPatentWatchPost-Approval Patent Strategy: How to Protect Your Drug from Regulatory and IP Risk After ApprovalThis article examines how pharmaceutical companies can integrate patent intelligence into post-approval change (PAC) management following two significant Federal Circuit rulings that tightened Orange Book listing requirements. The December 2024 Teva v. Amneal decision established that device patents must claim the active pharmaceutical ingredient to qualify for Orange Book listing, while the 2023 Jazz v. Avadel ruling excluded REMS system patents from method-of-use listings. Merck's Keytruda Qlex subcutaneous formulation serves as the primary case study, demonstrating how a $1 billion development investment in reformulation can protect $9 to $12 billion in annual revenue past the original 2028 IV patent expiry through new regulatory approvals and patent estates potentially extending to 2042. The article provides a four-question IP screening framework for PAC decisions and discusses the FTC's sustained enforcement campaign that challenged over 600 patents across three rounds between 2023 and 2025.Seeking AlphaAlkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS)Alkermes plc maintains a Buy rating driven by the accretive acquisition of Avadel Pharmaceuticals and strong early sales momentum from LUMRYZ in the hypersomnolence portfolio. The company reported positive phase 2 data for alixorexton in narcolepsy type 2, with ongoing phase 3 Brilliance Studies supporting a growth thesis. Alkermes projects full-year 2026 revenues of $1.73 to $1.84 billion across its four approved drugs, though risks around phase 3 trials and integration remain.Grand View ResearchSleep Aids Market Size, Share & Growth Report, 2026-2033Grand View Research published a market analysis report showing the global sleep aids market was valued at USD 49.1 billion in 2025 and is projected to reach USD 95.2 billion by 2033, growing at a CAGR of 8.7%. The insomnia segment held the largest market share at 32.5% in 2025, while North America dominated regionally with 36.4% revenue share. Notable recent strategic transactions include Eli Lilly's planned acquisition of Centessa Pharmaceuticals to expand its orexin receptor agonist pipeline for sleep-wake disorders, and Alkermes' acquisition of Avadel Pharmaceuticals to gain access to its narcolepsy drug Lumryz.EIN PresswireNarcolepsy Market 2026: Competitive Trends Shaping Industry LeadershipJazz Pharmaceuticals led global narcolepsy sales in 2024 with a 43% market share, while the top 10 players held 76% of total revenue. The market is highly concentrated, with leading firms including Harmony Biosciences, Avadel, and Axsome. Once-nightly oxybate therapies like Avadel's LUMRYZ are transforming treatment adherence.FiercePharmaAlkermes’ Lumryz hits phase 3 mark in another sleep disorder, fueling momentum from $2.4B Avadel acquisitionAlkermes reported that its sodium oxybate Lumryz met all primary and key secondary endpoints in a phase 3 trial for idiopathic hypersomnia. The company plans to file for FDA approval by the end of 2026, with a potential 2028 launch. The drug's sales are expected to reach $350–370 million this year.openPR.comTop Companies and Industry Competition in the Sleeping Aids MarketThe sleeping aids market is projected to reach $137.07 billion by 2030 with a 7.6% CAGR, driven by aging populations, wearable technology adoption, and rising sleep disorder diagnoses. In October 2025, Ireland-based biopharmaceutical company Alkermes Plc acquired Avadel Pharmaceuticals for $2.1 billion to expand its sleep medicine portfolio, while US-based EnsoData partnered with React Health in October 2023 to improve patient adherence to sleep apnea therapy.openPR.comHypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsightDelveInsight's 'Hypersomnia Pipeline Insight, 2026' report identifies more than three pharmaceutical companies actively developing over four treatment candidates for hypersomnia, signaling growing innovation in this sleep disorder therapeutic area. Axsome Therapeutics reported positive Phase III results for AXS-12 in November 2024, Avadel Pharmaceuticals received FDA orphan drug designation for Lumryz in June 2025, and Alkermes initiated a Phase II trial for ALKS 2680 in April 2025. Additional companies including Zevra Therapeutics are also advancing treatment candidates such as KP1077 through the pipeline.